Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia

Basit Öğe Kaydı
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridYesilada, Elif/0000-0002-3743-5767
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYesilada, Elif/ABG-9600-2020
dc.contributor.authorGulbay, Gonca
dc.contributor.authorYesilada, Elif
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBag, Harika Gozukara
dc.contributor.authorKuku, Irfan
dc.contributor.authorKaya, Emin
dc.date.accessioned2024-08-04T20:09:59Z
dc.date.available2024-08-04T20:09:59Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Detection of JAK2 V617F in myeloproliferative neoplasms (MPNs) is very important in both diagnosis and disease progression. In our study, we investigated the frequency of JAK2 V617F mutation in patients with myeloproliferative disorders. Methods: We retrospectively reviewed the records of 720 patients (174 females and 546 males) who were tested for JAK2 V617F mutation from January 2007 to December 2017. Results: In our patients were determined 22.6% JAK2 V617F mutation. 33.3% in women, 19.2% in men have been positive for JAK2 V617F mutation. In our study JAK2 V617F present in 48.6% of essential thrombocythemia, 80.5% of polycythemia rubra vera (PV), 47.5% of primary myelofibrosis, 10% of MPNs, unclassifiable, 0.8% of others. We also investigated the difference in hematological parameters [white blood cell, hemoglobin (Hb), hematocrit (HCT), red blood cell distribution widths (RDW) and platelets count (PLT)] between JAK2 V617F positive and JAK2 V617F negative patients. Conclusions: Investigation of the JAK2 V617F mutation is very important in cases of MPNs. In our study JAK2 V617F mutation was higher in PV, essential thrombocythemia, and primary myelofibrosis patients. However, there were significant differences in Hb, HCT, RDW and PLT levels in mutation-positive patients.en_US
dc.identifier.doi10.1515/tjb-2018-0054
dc.identifier.endpage498en_US
dc.identifier.issn0250-4685
dc.identifier.issn1303-829X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85073555755en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage492en_US
dc.identifier.trdizinid340509en_US
dc.identifier.urihttps://doi.org/10.1515/tjb-2018-0054
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/340509
dc.identifier.urihttps://hdl.handle.net/11616/92547
dc.identifier.volume44en_US
dc.identifier.wosWOS:000489303900010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofTurkish Journal of Biochemistry-Turk Biyokimya Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectJanus Kinase2en_US
dc.subjectJAK-STAT pathwayen_US
dc.subjectMyeloproliferative disordersen_US
dc.subjectJAK2 V617F mutationen_US
dc.subjectReal-time poly-merase chain reactionen_US
dc.titleEvaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatoliaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu